Altimmune
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Maryland, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
910 Clopper Rd Ste 201S, Gaithersburg, M...Phone Number
(240) 654-1450Website
www.altimmune.comRevenue
<$5 MillionStock Symbol
ALTIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
2
About Altimmune
Altimmune is a late clinical-stage biotechnology company focused on developing innovative therapies for serious liver, metabolic, and obesity-related diseases, with a primary emphasis on advancing its lead drug candidate, pemvidutide, which is designed to target key biological pathways involved in these conditions, while leveraging scientific research and clinical trials to create effective treatments that address unmet medical needs and improve patient outcomes through novel therapeutic approaches in the healthcare sector.Explore more
Altimmune Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Altimmune your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Altimmune has new funding data
Altimmune, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Altimmune recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Altimmune launches new products
Click to see if Altimmune had a recent Job posting/layoffs
Check out if Altimmune is spiking on competitors!
Check if Altimmune has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Altimmune
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Altimmune as Masked Content
Find 2 more new buyers
Compare Similar Companies to Altimmune
Compare insights from companies similar to Altimmune, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Altimmune is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Altimmune is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Altimmune.
Altimmune financials insights
Gather financial insights about Altimmune, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Multiple Rounds
$66M
2020
Debt
$350K
Grant
$4.7M
2026
Unspecified
$225M
Altimmune Tech Stack
A closer look at the technologies used by Altimmune
Most Recent Scoops
Facilities Relocation / Expansion
Altimmune is planning to move offices in October 2026. The move will impact approximately 15 employees at the existing office located at 910 Clopper Rd, Gaithersburg, MD.
Facilities Relocation/Expansion
Event
Product Marketing, Events, Engineering, Contingent Workforce, Sales, Outsourcing, Bioengineering, Chemical Engineering, Field /Outside Sales, Field Marketing
Left Company
Executive Move
Executive Moves, Left Company
Project
Altimmune has two cohorts one focused on biopsy-proven patients and one on non-invasive test (NIT) criteria allowing sites to enroll patients through either pathway, a design that has received positive feedback from principal investigators.
Clinical Operations
Project
Medical Research
Altimmune News & Media
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
Initiated global PERFORMA Phase 3 trial in MASHAltimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026.Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH
Global registrational study designed to evaluate pemvidutide on fibrosis improvement, MASH resolution, and clinical outcomesAltimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial
Altimmune (NASDAQ:ALT) reported positive top-line results from its Phase II RECLAIM trial evaluating pemvidutide in adults with moderate to severe alcohol use disorder, or AUD, with the company saying the study met its primary endpoint and several secondary measures after 24 weeks of treatment. The
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Altimmune
Sign Up For FreeTo access detailed company insights
Altimmune is a late clinical-stage biotechnology company focused on developing innovative therapies for serious liver, metabolic, and obesity-related diseases, with a primary emphasis on advancing its lead drug candidate, pemvidutide, which is designed to target key biological pathways involved in these conditions, while leveraging scientific resea... Read More
